◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

川宁生物

川宁生物
Loading...
Price History
Market Data
Market Cap24.5B
Market Cap (USD)$3.4B
P/E Ratio-
P/B Ratio-
EPS0.63
Dividend Yield-
D/E Ratio0.33
Current Ratio2.13
Market SegmentChiNext
CurrencyCNY
Business Overview

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ekdoin, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop planting, inspection, technical advisory, and asset investment activities. The company was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

证监会行业分类 C27医药制造业 SZSE
Key Financial Metrics
5.8B
Revenue
1.4B
Net Income
0.63
EPS (Diluted)
1.7B
Free Cash Flow
Profitability
Gross Margin -
Operating Margin 29.3%
Net Profit Margin 24.3%
EBITDA 1.7B
Returns & Efficiency
Return on Assets (ROA) 13.3%
Return on Equity (ROE) 17.7%
Dividend Yield -
EPS 0.63
Financial Health
Total Assets 10.6B
Total Debt 2.6B
Debt to Equity 0.33x
Current Ratio 2.13
Company Info
IndustryC27医药制造业
Market SegmentChiNext
CurrencyCNY
Fiscal Year2024
Peers
2.7T
P/E: 7.6
2.5T
P/E: 7.2
2.4T
P/E: 8.7
CNOOC LIMITED
600938
2.0T
P/E: 16.2
1.9T
P/E: 25.6
1.8T
P/E: 20.1
1.8T
P/E: 7.3
1.2T
P/E: 6.9
Stock Chart
Open Full Chart View

Full charting with technical indicators, candlestick, line charts, and more.

Company Profile
General Information
Company Name川宁生物
Ticker301301
ExchangeSZSE
Sector证监会行业分类
IndustryC27医药制造业
Market SegmentChiNext
Fiscal Year2024
CurrencyCNY
Financial Summary
Market Cap24.5B
Market Cap (USD)$3.4B
Revenue5.8B
Net Income1.4B
P/E Ratio-
EPS0.63
Net Margin24.3%
ROE17.7%
Dividend Yield-
Description

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ekdoin, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop planting, inspection, technical advisory, and asset investment activities. The company was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...